Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy

Degenerative Neurological and Neuromuscular Disease ◽

10.2147/dnnd.s224912 ◽

2020 ◽

Vol Volume 10 ◽

pp. 29-38 ◽

Cited By ~ 1

Author(s):

Carolyn H Goldschmidt ◽

Le H Hua

Keyword(s):

Multiple Sclerosis ◽

Relapsing Multiple Sclerosis

Download Full-text

Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis

10.26226/morressier.59a3eda8d462b8028d8952ea ◽

2017 ◽

Author(s):

Ludwig Kappos

Keyword(s):

Multiple Sclerosis ◽

Disability Progression ◽

Relapsing Multiple Sclerosis

Download Full-text

Association of brain volume loss and NEDA outcomes in patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies

10.26226/morressier.59a3eda9d462b8028d89576b ◽

2017 ◽

Cited By ~ 1

Author(s):

Anthony Traboulsee

Keyword(s):

Multiple Sclerosis ◽

Brain Volume ◽

Volume Loss ◽

Brain Volume Loss ◽

Relapsing Multiple Sclerosis

Download Full-text

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

Case Medical Research ◽

10.31525/ct1-nct03853746 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Cell Depletion ◽

B Cell Depletion ◽

Short Term ◽

Relapsing Multiple Sclerosis

Download Full-text

Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)

Case Medical Research ◽

10.31525/ct1-nct04121065 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Relapsing Multiple Sclerosis

Download Full-text

Faculty Opinions recommendation of Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257599.793501670 ◽

2014 ◽

Author(s):

Hugh Rosen

Keyword(s):

Multiple Sclerosis ◽

Japanese Patients ◽

Phase 2 ◽

Relapsing Multiple Sclerosis

Download Full-text

Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients

Journal of Clinical Immunology ◽

10.1023/b:joci.0000025450.48267.a5 ◽

2004 ◽

Vol 24 (3) ◽

pp. 287-293 ◽

Cited By ~ 22

Author(s):

Giovanni Frisullo ◽

Francesco Angelucci ◽

Massimiliano Mirabella ◽

Marcella Caggiula ◽

Katia Patanella ◽

...

Keyword(s):

Multiple Sclerosis ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells ◽

Multiple Sclerosis Patients ◽

Relapsing Multiple Sclerosis

Download Full-text

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies

Advances in Therapy ◽

10.1007/s12325-021-01865-w ◽

2021 ◽

Author(s):

Gavin Giovannoni ◽

Giancarlo Comi ◽

Kottil Rammohan ◽

Peter Rieckmann ◽

Fernando Dangond ◽

...

Keyword(s):

Multiple Sclerosis ◽

Expanded Disability Status Scale ◽

Post Hoc Analysis ◽

Disability Status ◽

Post Hoc ◽

Relapsing Multiple Sclerosis

Download Full-text

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of phase 3 ozanimod trials

European Journal of Neurology ◽

10.1111/ene.15009 ◽

2021 ◽

Author(s):

Sarah Harris ◽

Giancarlo Comi ◽

Bruce A. C. Cree ◽

Douglas L. Arnold ◽

Lawrence Steinman ◽

...

Keyword(s):

Multiple Sclerosis ◽

Light Chain ◽

Phase 3 ◽

Neurofilament Light Chain ◽

Neurofilament Light ◽

Post Hoc Analysis ◽

Post Hoc ◽

Relapsing Multiple Sclerosis

Download Full-text

Dimethyl fumarate for treating relapsing multiple sclerosis

Expert Opinion on Drug Safety ◽

10.1517/14740338.2015.977251 ◽

2014 ◽

Vol 14 (1) ◽

pp. 161-170 ◽

Cited By ~ 22

Author(s):

William Sheremata ◽

Andrew D Brown ◽

Kottil W Rammohan

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Relapsing Multiple Sclerosis

Download Full-text

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

The Lancet Neurology ◽

10.1016/s1474-4422(06)70327-1 ◽

2006 ◽

Vol 5 (3) ◽

pp. 213-220 ◽

Cited By ~ 56

Author(s):

Massimo Filippi ◽

Jerry S Wolinsky ◽

Giancarlo Comi

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Glatiramer Acetate ◽

Controlled Study ◽

Double Blind ◽

Relapsing Multiple Sclerosis

Download Full-text